Synopsis
The symposium on Medicinal Chemistry in Eastern England is a highly successful, long-standing, one-day meeting which runs annually. The symposium, known colloquially as the "Hatfield MedChem" meeting, will comprise presentations covering various aspects of drug discovery, including medicinal chemistry case studies and SBDD, as well as more general topics related to medicinal chemistry and drug discovery. The meeting will be applicable to all those working in medicinal chemistry and drug discovery. In addition, the meeting will offer excellent networking opportunities.
Exhibition
The relevant trade exhibition will add value to the symposium. Exhibition stand space only is priced at 拢205 excluding any attendees. The exhibition will be held in the same room as the catering (refreshments and lunch), and details of the exhibition package may be found on the event website. The exhibition consistently sells out, so early booking is recommended.
Programme
09.00 Registration, refreshments and exhibition
Session chair: Adrian Hall, UCB
09.30 Opening remarks
Nicole Hamblin, GlaxoSmithKline
09.35 From phenotypic hit to a validated target for tuberculosis
Robert Bates, GlaxoSmithKline
10.10 Discovery of potent inhibitors of the lysophospholipase autotaxin
Prit Shah, Cancer Research Technology
10.45 Refreshments and exhibition
11.15 Development of Tesirine: a clinical antibody-drug conjugate pyrrolobenzodiazepine payload: medicinal chemistry at the frontier between small molecules and biologics
Arnaud Tiberghien, Spirogen
11.50 NMR conformational analysis in molecular design 鈥� case studies and impact
Martin Packer, AstraZeneca
12.25 Highly potent cell-penetrant inhibitors of the KEAP1-NRF2 protein-protein interaction via X-ray fragment screening
Charlotte Griffiths-Jones, Astex Pharmaceuticals
13.00 Lunch and exhibition
Session Chair: Simon Ward, University of Sussex
14:05 Selective on-target chemical probes of protein-protein interactions
Alessio Ciulli, University of Dundee
14.40 Solid state studies of a preclinical candidate in a CRO environment: the importance of de-risking early
Russell Scammell, Charles River
15.15 Refreshments and exhibition
15.45 Inhibitors of the mitotic kinase MPS1: From screening hits to a preclinical drug candidate
Swen Hoelder, Institute of Cancer Research
16.20 Optimisation of a series of novel smoothened inhibitors
Matilda Bingham, RedX
16.55 Concluding remarks
17.00 Close
The symposium on Medicinal Chemistry in Eastern England is a highly successful, long-standing, one-day meeting which runs annually. The symposium, known colloquially as the "Hatfield MedChem" meeting, will comprise presentations covering various aspects of drug discovery, including medicinal chemistry case studies and SBDD, as well as more general topics related to medicinal chemistry and drug discovery. The meeting will be applicable to all those working in medicinal chemistry and drug discovery. In addition, the meeting will offer excellent networking opportunities.
Exhibition
The relevant trade exhibition will add value to the symposium. Exhibition stand space only is priced at 拢205 excluding any attendees. The exhibition will be held in the same room as the catering (refreshments and lunch), and details of the exhibition package may be found on the event website. The exhibition consistently sells out, so early booking is recommended.
Programme
09.00 Registration, refreshments and exhibition
Session chair: Adrian Hall, UCB
09.30 Opening remarks
Nicole Hamblin, GlaxoSmithKline
09.35 From phenotypic hit to a validated target for tuberculosis
Robert Bates, GlaxoSmithKline
10.10 Discovery of potent inhibitors of the lysophospholipase autotaxin
Prit Shah, Cancer Research Technology
10.45 Refreshments and exhibition
11.15 Development of Tesirine: a clinical antibody-drug conjugate pyrrolobenzodiazepine payload: medicinal chemistry at the frontier between small molecules and biologics
Arnaud Tiberghien, Spirogen
11.50 NMR conformational analysis in molecular design 鈥� case studies and impact
Martin Packer, AstraZeneca
12.25 Highly potent cell-penetrant inhibitors of the KEAP1-NRF2 protein-protein interaction via X-ray fragment screening
Charlotte Griffiths-Jones, Astex Pharmaceuticals
13.00 Lunch and exhibition
Session Chair: Simon Ward, University of Sussex
14:05 Selective on-target chemical probes of protein-protein interactions
Alessio Ciulli, University of Dundee
14.40 Solid state studies of a preclinical candidate in a CRO environment: the importance of de-risking early
Russell Scammell, Charles River
15.15 Refreshments and exhibition
15.45 Inhibitors of the mitotic kinase MPS1: From screening hits to a preclinical drug candidate
Swen Hoelder, Institute of Cancer Research
16.20 Optimisation of a series of novel smoothened inhibitors
Matilda Bingham, RedX
16.55 Concluding remarks
17.00 Close
